What's
New at
Labrix?
DPD
Simple, non-invasive urine test to track your patients' rate of bone loss. Pair this test with hormone and adrenal panels.
Learn more here.
DNA
FindWhyTM Weight Control Panel for Genetic Tendencies. DNA sample is collected from a non-invasive cheek swab.
Learn more here.
DHT
Acne, hair loss or hirsutism
a concern for your patients? Consider adding DHT to
their saliva test.
February 4, 2015
50 Shades of Heart Health

In February we focus on matters of the heart; both the figurative and the literal. Love, romance, courtship and passion are front and center in Hollywood, with the theatrical release of 50 Shades of Grey falling on Valentine’s Day. This month is also American Heart Month: a time to review and learn about reducing risks and sequelae of heart disease. Cardiovascular fitness and sexual function share more than a spot on the calendar: both are significantly impacted by hormone imbalance. The connection between healthy hormone levels and their effect on romance, libido and sexual preparedness are reasonably well known; and the interrelationship between cardiovascular health and hormonal balance is lesser known yet equally important.

In women, estrogen deficiency often leads to vaginal dryness, atrophy and diminished vaginal sensation, which are major contributors to the loss of libido and disinterest in physical intimacy. In addition to restoring tissue integrity through topical application to vaginal tissue, bioidentical hormone replacement therapy in general has been shown to increase sexual desire in women. Transdermal estradiol has a cardioprotective effect in postmenopausal women and reduces the incidence of diabetes, which is a significant risk factor for heart attacks. Additionally, micronized progesterone can have a beneficial effect on blood pressure, another contributing factor to heart disease. Unlike oral estrogens and synthetic progestins, transdermal bioidentical estradiol and progesterone do not increase the risk of venous thromboembolism in women.

There is a strong connection between male sexual dysfunction and cardiovascular disease - atherosclerosis, hypertension, elevated cholesterol and established cardiovascular disease often go hand in hand with erectile dysfunction, and are greatly influenced by hormonal health. Testosterone replacement therapy has exhibited beneficial cardiovascular effects including improving insulin resistance, increasing exercise tolerance, increasing muscle mass, and contributes to coronary artery vasodilation, suggesting that optimal testosterone levels actually decrease the risk of cardiovascular disease. On the sexual front, testosterone therapy is effective in restoring sexual desire and function and has a 35-40% success rate in reversing erectile dysfunction.

Tying it all together (no pun intended, for fans of the book), balanced hormone levels may not only increase one’s interest in and enjoyment of a healthy sex life, but may also contribute to a healthy cardiovascular system enabling greater tolerance for, well… experimentation.

References:
  • Woods NF, et al. Sexual desire during the menopausal transition and early post-menopause: observations from the Seattle Midlife Women’s Health Study. J Women's Health. 2010; 19: 209-18.
  • Chism LA. Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy. Int J Womens Health. 2012; 4: 551-57.
  • L ø kkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø . Hormone therapy and risk of myocardial infarction:a national register study. Eur Heart J 2008;29:2660 – 8
  • de Lauzon-Guillain B, Fournier A, Fabre A, e t al . Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle G é n é rale de l’Education Nationale (E3N) cohort. Diabetologia 2009;52:2092 – 100
  • Albrecht-BetancAndrogen ourGuay, AT. Testosterone and erectile physiology. Aging Male. 2006; 9: 201-6.t M, et al. replacement in men with hypogonadism and erectile dysfunction . Endocrine. 2004; 23: 143-8.
  • Oskui P, French W, Herring M, et al. Testosterone and the Cardiovascular System: A Comprehensive Review of the Clinical Literature. J Am Heart Assoc. 2013 Dec; 2(6): e000272. • Conners WP
  • SR. Erectile dysfunction and comorbid diseases, androgen deficiency, and diminished libido in men. J Am Osteopath Assoc. 2004Fine ; 104: S9-15.
  • Albrecht-BetancAndrogen ourGuay, AT. Testosterone and erectile physiology. Aging Male. 2006; 9: 201-6.t M, et al. replacement in men with hypogonadism and erectile dysfunction . Endocrine. 2004; 23: 143-8.

Labrix Celebrates its 10th Anniversary!

Labrix co-founders Dr. Erin Lommen and Dr. Jay Mead sit down for a short interview and discuss the company's first ten years, as well as its bright future with diagnostic testing.




Labrix
Core Training
Chicago, IL
March 14, 2015

Registration is $150 and upon completing this one day training, you will receive a $100 credit on your testing account. Register for Atlanta Core Training today.


Labrix
Core Training
Chicago, IL
May 16, 2015

Can't make it to Atlanta? Labrix staff physicians will be in Chicago on May 16 to present Core Training. Registration is $150 and upon completing this one day training, you will receive a $100 credit on your testing account. Register for Chicago Core Training today.


SAVE THE DATE
Labrix
Core Training
Portland, OR
August 1, 2015

IHS
New York, NY
Feb. 19-21, 2015

Labrix' co-founder Dr. Lommen will be hosting a breakfast session at IHS, speaking on the topic of "Gaining Success in Weight Loss: Clinical Protocols for Advanced Practitioners."

Click here for more information and to secure your FREE spot at the breakfast session! (Must be registered to attend IHS 2015 to attend breakfast session)